Lloyd Mayer
- CO-DIRECTOR IMMUNOLOGY INSTITUTE
- PROFESSOR Medicine, Gastroenterology
- PROFESSOR Medicine, Clinical Immunology
- PROFESSOR Microbiology
Print Profile
Specialty
Certifications
Gastroenterology
American Board of Internal Medicine
Clinical Focus
Research Topics
Training Areas
Education
MD, Mount Sinai School of Medicine
Residency, Internal Medicine
New York University Medical CenterFellowship, Gastroenterology
Mount Sinai Hospital
Biography
Dr. Mayer is Professor and Co-Director of the Immunology institute, Dorothy and David Merksamer Professor of, Medicine, and Professor of Microbiology at the Mount Sinai Medical Center. He graduated with a BS in Biology (Sigma Xi) from Union College (1996) and his MD (AOA) from the Mount Sinai Medical School in 1976 where he received the Mosby Award for Clinical Excellence. Dr. Mayer did his internship and residency in Internal Medicine at Bellevue/New York University (1976-1979) and completed his Gastroenterology fellowship at the Mount Sinai Medical Center in 1981. Dr. Mayer is a diplomate of the American Board of Internal Medicine with subspecialty certification in Gastroenterology.
From 1980 through 1984, Dr. Mayer held joint appointments at Rockefeller University and Mount Sinai Medical Center. He pursued his immunology interests in the laboratory of the late Dr. Henry Kunkel. He became Associate Professor of Medicine and Microbiology at Mount Sinai (1985 -1986) and the Director of the Division of Clinical Immunology (1986). Dr. Mayer received the Saul Horowitz Award and the Irma T. Hirschl Trust Career Development Award in 1986. Shortly after achieving full Professorships in Medicine and Microbiology in 1990, Dr. Mayer became Vice Chair of Medicine at the Mount Sinai Medical Center. He also received the Jeffrey Modell Foundation Lifetime Achievement Award. In 1994 Dr. Mayer was named the David and Dorothy Merksamer Chair of Medicine. In 1997 he became Professor of Immunobiology and Chair of the Immunobiology Center at the Mount Sinai Medical Center. In 2007 he became Professor and Co-Director of the Immunology Institute. He was also the Director of the Division of Gastroenterology (2003-2010) and is the Chairman of the National Scientific Advisory Committee of the CCFA since 2008.
Dr. Mayer’s research has focused on mucosal immunoregulation, inflammatory bowel disease and cytokine regulation of human B-cell differentiation. He has focused attention on the role of intestinal epithelial cells (IEC) in regulatory T-cell responses in the gut. He has focused on the major role that T-cell defects play in the pathogenesis of inflammatory bowel disease.
In 1991 Dr. Mayer was elected to membership in the American Society for Clinical Investigation and the Association of American Physicians in 1997. In 1998 Dr. Mayer won the Jaffe Food Allergy Institute Award for Scientific Excellence. He was the recipient of the 2000 Crohn’s and Colitis Foundation of America (CCFA) Scientific Achievement Award. From 1992-1997 he served on the Immunological Sciences Study Section of the NIH. He currently has five active NIH grants on immunoregulatory mechanisms and responses in the intestine (IBD and food allergy) and is the PI of the Immunobiology training grant. He is currently the principle investigator of a PPG on innate and adaptive mucosal immune responses/inflammatory bowel disease, an RO1 on the development of an oral vaccine to Yersinia pestis, a challenge grant (ARRA) on the generation and characterization of CD8+ regulatory T cells from the intestine, a U19 grant on milk allergy (PI of one project), a co-PI on a U19 grant focused on peanut and egg allergy (PI of the mechanistic studies), and the PI of a core (flow cytometry) in a program project grant on primary immunodeficiency.
Mailing Address:
Mount Sinai Medical Center
1425 Madison Avenue, Suite 11-20
Box 1089
New York, NY 10029
Tel: (212-659-9266
Fax: (212-987-5593
Awards
2009 -
Best Doctors
New York Magazine
Research
Specific Clinical/Research Interests: Regulation of mucosal immune responses; antigen presentation by intestinal epithelial cells?
Current Students: Keren Rabinowitz, Lauren Peters, David Chiang
Postdoctoral Fellows: David Dunkin, Zara Hovhannisyan, Giulia Roda, Alina Iuga
Research Assistants: Kelly Ramin, Sarah Fasio
Summary of Research Studies:
Our laboratory studies the regulation of mucosal immune responses in both human and murine systems. Specifically we focus on the role that intestinal epithelial cells play in this process. Intestinal epithelial cells express non-classical class I molecules that are involved in the activation of unique populations of regulatory T cells. They also express a tumor associated antigen, carcinoembryonic antigen, that, along with CD1d, activates a population of CD8+ Tregs called TrE cells. Current studies focus on the characterization of different Treg populations (CD8 and CD4+) in the intestine as well as different CEA subfamily members and their ability to interact with distinct class Ib molecules. These studies have extended into the role of such cells in fetal/maternal interactions where activation of distinct Treg populations may occur restricted by other CEA subfamily members. Other studies in murine systems look at the role of CD8+ Tregs in the induction of oral tolerance. Finally, we are interested in translating these findings into human disease. We have developed models of abnormal antigen presentation in inflammatory bowel disease (Crohn's disease and ulcerative colitis). Epithelial cells derived from surgical specimens from these patients fail to activate TrE cells but rather activate inflammatory CD4+ T cells. Defects in class Ib and CEA expression appear to be responsible for this finding. Defining mechanisms involved in the failure to express these regulatory surface molecules is a current focus. This has been translated into in vivo assessments. We have also identified defects in oral tolerance in these patients. The mechanisms involved in the generation of oral tolerance in normal controls as well as the mechanisms involved in the defect in oral tolerance in IBD patients are also being studied.
Publications:Mayer, L, W Pandak, G Melmed, S Hanauer, K Johnson, D Payne, H Falek, R Hariri and S Fischkoff. 2012. Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant Crohn’s disease: a Phase 1 study. IBD Journal in press
Rabinowitz KM, Y Wang, E Chen, Z Hovhannisyan, MC Berin, S Dahan, D Chaussabel, A Ma’ayan, L Mayer. 2012. Transforming-growth-factor beta signaling controls the activity of human intestinal CD8+ T suppressor cells. Gastroenterology In revision
Kenny EE, Pe’er I, Karban A, Ozelius L, Mitchell AA, Ng SM, Erazo M, Ostrer H, Abraham C, Abreu MT, Atzmon G, Barzilai N, Brant S, Burns ER, Chowers Y, Clark LN, Darvasi A, Doheny D, Duerr RH, Eliakim R, Giladi N, Gregersen PK, Hakonarson H, Jones MR, McGovern DPB, Mulle J, Orr-Urtreger A, Proctor DD, Pulver A, Rotter JI, Silverberg MS, Ullman T, Warren ST, Waterman M, Zhang W, Bergman A, Mayer L, Katz S, Desnick RJ, Cho JH, Peter 2012. A Genome-Wide Scan of Ashkenazi Jewish Crohn’s Disease Suggests Novel Susceptibility Loci. PLoS Genet (accepted/in press)
Shulzhenko N, A Morgun, W Hsiao, M Battle, M Yao, O Gavrilova, M Orandle, L Mayer, AJ Macpherson, KD McCoy, C Fraser-Liggett and P Matzinger. 2011. Immunity vs. metabolism in the gut: cross-talk between B lymphocytes, microbiota and the intestinal epithelium. Nature Medicine. 17(12):1585-93
Ouyang X, R Zhang, J Yang, Q Li, L Qin, C Zhu, J Liu, H Ning, MS Shin, M Gupta, C-F Qi, JC He, SA Lira, HC Morse III, K Ozato, L Mayer and H Xiong. 2011. Transcription factor IRF8 directs a silencing program for TH17 cell differentiation. Nature Communications 2:314:1-12
Dunkin D, M. C Berin, and L Mayer. 2011. Allergic Sensitization to Cow’s Milk Antigens Can Be Induced via Multiple Physiologic Routes in an Adjuvant-Dependent Manner. JACI 128(6):1251-1258
Dotan, I, L Werner, S Vigodman, S Agarwal, J Pfeffer, N Horowitz, L Malter, M Abreu, T Ullman, H Guzner-Gur, Z Halpern, L Mayer. 2012. Normal Response to Vaccines in Inflammatory Bowel Disease Patients Treated with Thiopurines. IBD Journal 18:261–268
Hovhannisyan Z, J Treatman, D Littman and L Mayer. 2011. Characterization of IL-17-producing regulatory T cells in inflamed gut mucosa. Gastroenterology 140(3):957-65
Fukata, M, L Shang, R Santaolalla, J Sotolongo, C Pastorini, C España, R Ungaro, N Harpaz, HS Cooper, G Elson, M Kosco-Vilbois, J Zaias, MT. Perez, L Mayer, AS Vamadevan, SA Lira and MT. Abreu. 2011. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis IBD Journal 17(7):1464-73
Dahan S, K Rabinowitz, AP Martin, MC Berin, JC Unkeless and L Mayer. 2011. The Notch-1 signaling pathway regulates intestinal epithelial barrier function in mice and humans through interaction with CD4+ T cells. Gastroenterology 140:550-9
Yu JE, De Ravin SS, Uzel G, Landers C, Targan S, Malech HL, Holland SM, Cao W, Harpaz N, Mayer L, Cunningham-Rundles C. 2011. High Levels of Crohn's Disease-Associated Anti-Microbial Antibodies Are Present and Independent of Colitis in Chronic Granulomatous Disease Clin Immunol 138(1):14-22. PMID:20956091
Bongers G, D Maussang, LR Muniz, VM Noriega, A Fraile-Ramos, N Barker, F Marchesi, N Thirunarayanan, HF Vischer, L Qin, L Mayer, N Harpaz, R Leurs, GC Furtado,H Clevers, D Tortorella, MJ Smit,2 and SA Lira. 2010. The cytokine-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. JCI 120:3969-78
Viejo-Borbolla A, AP Martin, LR Muniz, L Shang, F Marchesi, N Thirunarayanan, N Harpaz, RA Garcia, M Apostolaki , GC Furtado, L Mayer, G Kollias, A Alcami, and SA Lira. 2010. Attenuation of TNF-driven murine ileitis by intestinal expression of the viral immunomodulator CrmD. Mucosal Immunology 3:633-44
Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ. 2010. .Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 16:620-9.
Roda G, Caponi A, Benevento M, Nanni P, Mezzanotte L, Belluzzi A, Mayer L, Roda A. 2010. New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflamm Bowel Dis. 16:1239-46.
Blázquez AB, Mayer L, Berin MC. 2010. Thymic Stromal Lymphopoietin is Required for Gastrointestinal Allergy but not Oral Tolerance. Gastroenterology 138:275-84
WJ Sandborn, J-F Colombel, M Frankel, D Hommes, J Lowder, L Mayer, S Plevy, P Stokkers, S Travis, G Van Assche, D Baumgart, and S Targan. 2010. Anti-CD3 Antibody Visilizumab is Not Effective in Patients with Intravenous Corticosteroid-Refractory Ulcerative Colitis. Gut 59:1485-92
Murphy SJ, Mayer L, Abreu MT. 2010. Mesalamine (5-Aminosalicylic Acid) Therapy Well Tolerated in a Patient With Aspirin Hypersensitivity and Ulcerative Colitis. J Clin Gastroenterol. 45(1):83-4
Sicherer SH, Wood RA, Stablein D, Burks AW, Liu AH, Jones SM, Fleischer DM, Leung DY, Grishin A, Mayer L, Shreffler W, Lindblad R, Sampson HA. Immunologic features of infants with milk or egg allergy enrolled in an observational study (Consortium of Food Allergy Research) of food allergy. J Allergy Clin Immunol. 2010 125:1077-1083
Blázquez AB, Knight AK, Getachew H, Bromberg JS, Lira SA, Mayer L, Berin MC. A Functional Role for CCR6 on Proallergic T Cells in the Gastrointestinal Tract. Gastroenterology. 2010. 138:275-284 PMID: 19782082
Nguyen HT, Dalmasso G, Yan Y, Laroui H, Dahan S, Mayer L, Sitaraman SV, Merlin D. 2010. MicroRNA-7 modulates CD98 expression during intestinal epithelial cell differentiation. J Biol Chem. 285(2):1479-89
Marchesi F, Martin AP, Thirunarayanan N, Devany E, Mayer L, Grisotto MG, Furtado GC, Lira SA. CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles. Mucosal Immunol. 2009 2(6):486-94. Epub 2009 Sep 9.PMID: 19741597
Baumgart DC, SR. Targan, AU. Dignass, L Mayer, Gvan Assche, DW. Hommes, SB. Hanauer, U Mahadevan, W Reinisch, SE. Plevy, BA. Salzberg, AL. Buchman, GM. Mechkov, ZA. Krastev, JN. Lowder, MB. Frankel, WJ. Sandborn. 2010. A prospective randomized multicenter phase I/II dose escalation trial of visilizumab (humanized anti-CD3 antibody) in severe steroid-refractory ulcerative colitis. IBD 16:620-629 PMID: 19714757
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Mayer during 2012 and/or 2013. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- 4SC AG; Amgen Inc.; BioLineRx, Ltd.; Lexicon Pharmaceuticals, Inc.; Novo Nordisk; Pfizer Inc.; Proctor & Gamble
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Neovacs
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 11th Floor Room 11-20
1425 Madison Avenue
New York, NY 10029
Fax: 212-987-5593
5 East 98th Street
11th Floor
New York, NY 10029
Fax: 212-534-0971
- Monday 9:00am - 12:00pm
- Thursday 1:30pm - 5:00pm
- Medicare